Influencing Factors for Erectile Dysfunction of Young Adults with No Response to PDE5i

Curr Med Sci. 2021 Jun;41(3):529-534. doi: 10.1007/s11596-021-2380-8. Epub 2021 Jun 25.

Abstract

Erectile dysfunction (ED) is a common male disorder. Although orally-administered phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are now recognized as the primary pharmacological treatment method for ED, 20%-30% of the patients treated with PDE5 inhibitors exhibit no significant effects. This study aims to investigate the influencing factors of ED in young adults with no response to PDE5 inhibitors. ED patients who would take PDE5 inhibitors were included and investigated with a questionnaire. Patients with no response to PDE5 inhibitors (tadalafil and sildenafil) served as study group, and those with response to PDE5 inhibitors as control group. Then Chi square test and logistic regression analysis were applied to find the potential influencing factors. In total, 378 ED patients were included. Ninety-three (24.6%) cases were non-responsive to PDE5 inhibitors, and the remaining 285 (75.4%) responded to PDE5 inhibitors. In multiple logistic regression analysis, we found that history of drinking (OR=3.152; 95%CI 1.672-6.975), spousal noncooperation (OR=2.994; 95%CI 1.589-5.638), number of fixed sex partners (OR=0.358; 95%CI 0.132-0.651), duration of ED (OR=3.356; 95%CI 1.352-8.333), and depression (OR=3.689; 95%CI 1.579-8.979) could be the influencing factors for ED patients' non-response to PDE5 inhibitors. In conclusion, history of drinking, spousal noncooperation, number of fixed sex partner, long duration of ED, and depression could be the influencing factors for ED patients' non-response to PDE5 inhibitors. Patients and doctors should pay attention to these factors.

Keywords: PDE5 inhibitors; erectile dysfunction; influencing factor.

MeSH terms

  • Adolescent
  • Adult
  • Cyclic Nucleotide Phosphodiesterases, Type 5 / genetics*
  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / genetics
  • Erectile Dysfunction / pathology
  • Humans
  • Male
  • Middle Aged
  • Phosphodiesterase 5 Inhibitors / administration & dosage*
  • Phosphodiesterase 5 Inhibitors / adverse effects
  • Sildenafil Citrate / administration & dosage
  • Sildenafil Citrate / adverse effects
  • Tadalafil / administration & dosage
  • Tadalafil / adverse effects
  • Treatment Outcome
  • Young Adult

Substances

  • Phosphodiesterase 5 Inhibitors
  • Tadalafil
  • Sildenafil Citrate
  • Cyclic Nucleotide Phosphodiesterases, Type 5